Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556737 | 0.90 | SLC16A3 (0.53) | PTK2BSLC16A3HTR6IDH1FABP4 | |
| SCHEMBL3555571 | 0.90 | SLC16A3 (0.48) | PTK2BSLC16A3HTR6ALDH1A1IDH1 | |
| SCHEMBL3560333 | 0.87 | PTK2B (0.60) | PTK2BSLC16A3HTR6ALDH1A1MEN1 | |
| SCHEMBL3559119 | 0.87 | PTK2B (0.50) | PTK2BSLC16A3HTR6ALDH1A1MEN1 | |
| SCHEMBL3560911 | 0.86 | MEN1 (0.57) | SLC16A3ALDH1A1MEN1KMT2AIDH1 | |
| SCHEMBL3563988 | 0.86 | SLC16A3 (0.67) | SLC16A3ALDH1A1FABP4NR1I2 | |
| SCHEMBL3554638 | 0.85 | L3MBTL1 (0.56) | SLC16A3HTR6SMN1; SMN2NR1I2 | |
| SCHEMBL3561338 | 0.85 | HTR6 (0.62) | SLC16A3HTR6ALDH1A1ADRB2 | |
| SCHEMBL3556257 | 0.84 | SLC16A3 (0.67) | SLC16A3HTR6ALDH1A1MEN1KMT2A | |
| SCHEMBL3550800 | 0.84 | SLC16A3 (0.69) | SLC16A3ALDH1A1MEN1KMT2AIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | PTK2B 3187/4885SLC16A3 425/4885HTR6 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.